Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cudrania tricuspidata leaf refers to the foliage of the Cudrania tricuspidata tree, a plant from the Moraceae family native to East Asia and used extensively in traditional Korean, Chinese, and Japanese medicine. The leaves contain multiple bioactive phytochemicals, especially flavonoids (such as quercetin and kaempferol) and xanthones. Extracts derived from C. tricuspidata leaf have demonstrated anti-inflammatory, antioxidant, antitumor, hepatoprotective, neuroprotective, anti-obesity, and gastroprotective effects in various preclinical and some clinical studies. Mechanistically, the leaves exhibit their pharmacological effects primarily through inhibition of histamine H2 receptor-mediated gastric acid secretion, antioxidative pathways (notably Nrf2/HO-1 signaling), and cytochrome P450 enzyme inhibition (notably CYP1A2 and CYP2C8). The leaf extract has been evaluated for functional dyspepsia, digestive disorders, metabolic syndrome, and certain skin disorders associated with impaired tight junctions[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cudrania tricuspidata leaf.